Dozens of prescription drugs, from chemotherapy agents to common antibiotics, can damage the brain, spinal cord, or peripheral nerves. The list is broader than most people expect. Chemotherapy drugs are the most notorious culprits, but medications used to fight infections, prevent organ rejection, control seizures, and even run an MRI scan can all carry neurotoxic potential. The type and severity of nerve damage vary widely depending on the drug, the dose, and the individual, and understanding which medications pose a risk is the first step toward catching problems early.
Chemotherapy Drugs
Cancer chemotherapy is the single largest cause of drug-induced peripheral nerve damage, a condition doctors call chemotherapy-induced peripheral neuropathy (CIPN). Three major classes of chemotherapy drugs account for most cases: taxanes, platinum compounds, and proteasome inhibitors.
Taxanes like paclitaxel work by locking up the tiny structural filaments inside cells so cancer cells cannot divide. The problem is that those same filaments run the length of nerve fibers, and disrupting them damages the nerve’s internal transport system. In animal studies, paclitaxel causes swollen and damaged mitochondria in sensory nerve fibers, triggers abnormal calcium release inside cells, and injures the clusters of nerve cell bodies that sit along the spinal cord. Together, these changes produce the numbness, tingling, and pain in the hands and feet that many patients experience during treatment.1PubMed Central. Chemotherapy-Induced Peripheral Neuropathy: Current Status and Progress
Platinum-based drugs such as cisplatin and oxaliplatin take a different route to the same result. They accumulate in nerve cell bodies near the spinal cord and damage DNA, triggering cell death through oxidative stress and mitochondrial breakdown. Oxaliplatin also produces a distinctive acute form of nerve toxicity, likely caused by interference with sodium channels in nerve fibers, that can flare within hours of an infusion and cause cold-triggered tingling or jaw tightness. Cisplatin, meanwhile, directly damages mitochondrial DNA, a mechanism separate from its effect on nuclear DNA.1PubMed Central. Chemotherapy-Induced Peripheral Neuropathy: Current Status and Progress Bortezomib, a proteasome inhibitor used in blood cancers, also causes mitochondrial calcium release and sets off the same cell-death cascade seen with paclitaxel.
Both platinum drugs and aminoglycoside antibiotics share another form of neurotoxicity: damage to the inner ear. Cisplatin and aminoglycosides destroy the outer hair cells of the cochlea starting from the base, producing hearing loss that begins with high-pitched sounds and progresses downward. Aminoglycosides tend to also damage the vestibular system (the balance organs), while cisplatin is less likely to do so.2PubMed Central. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention
Antibiotics and Anti-Infective Drugs
Several widely used antibiotics can affect the nervous system. Fluoroquinolones (ciprofloxacin, levofloxacin, and their relatives) and macrolide antibiotics can cause neuropathy, insomnia, and even psychosis, driven in part by activation of excitatory receptors in the brain and oxidative stress. Linezolid, an antibiotic reserved for resistant infections, carries a risk of optic neuropathy (damage to the nerve connecting the eye to the brain) and can trigger serotonin syndrome when combined with other serotonin-boosting drugs. Glycopeptides like vancomycin and aminoglycoside antibiotics such as gentamicin are primarily linked to ototoxicity, meaning they damage the hearing and balance nerves.3PubMed Central. The Effect of Antibiotics on the Nervous System: Importance for Anesthesiology and Intensive Care
Metronidazole, a common antibiotic used for certain gut and pelvic infections, is another offender. Case reports have described both peripheral and central nervous system toxicity during treatment, though large-scale studies examining this association remain sparse.4PubMed Central. Metronidazole-associated Neurologic Events: A Nested Case-control Study The risk typically rises with prolonged courses or high cumulative doses, and the damage usually reverses once the drug is stopped, though not always completely.
Anti-Tuberculosis Drugs
Isoniazid (INH), the backbone of tuberculosis treatment worldwide, causes peripheral neuropathy through an indirect mechanism. Its action against the tuberculosis bacterium depletes pyridoxine (vitamin B6) in the body, and it is the resulting B6 deficiency that harms nerves.5Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. Peripheral neuropathy in persons with tuberculosis This is why patients on isoniazid are routinely given B6 supplements. There is an ironic twist, though: high doses of pyridoxine itself, above roughly 50 mg per day, can also be toxic to nerves.5Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. Peripheral neuropathy in persons with tuberculosis Getting the supplementation dose right matters.
Ethambutol, another first-line anti-TB drug, causes a different pattern of nerve injury. It chelates copper, and the resulting copper depletion leads to optic nerve damage and axonal degeneration.6PubMed Central. Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs Patients on ethambutol are typically monitored with regular vision checks so that optic neuropathy can be caught before it becomes irreversible. An expert consensus on vitamin B6 use has emphasized the importance of clear guidance on dosing, monitoring, and washout periods for patients whose treatment regimens put them at risk of B6-related complications.7PubMed Central. Expert Consensus on Vitamin B6 Therapeutic Use for Patients: Guidance on Safe Dosage, Duration and Clinical Management
Immunosuppressants
Tacrolimus, a cornerstone drug for preventing organ rejection after transplantation, works by blocking a signaling pathway in immune cells. But it can also cause a distinctive neurological emergency called posterior reversible encephalopathy syndrome (PRES), which typically appears within the first month after transplant.8PubMed Central. Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation PRES presents with headaches, seizures, vision changes, and confusion, often alongside a spike in blood pressure. Brain imaging shows swelling concentrated in the back of the brain.9PubMed Central. Tacrolimus-induced posterior reversible encephalopathy syndrome following liver transplantation
The “reversible” in the name is mostly accurate: with prompt recognition and dose reduction or drug switching, most patients recover. But the condition can become irreversible if it goes unrecognized, and tacrolimus is not the only calcineurin inhibitor that causes it. Cyclosporine, the older drug in the same class, carries a similar risk. Because transplant patients must stay on these drugs long-term, clinicians have to balance rejection prevention against neurological safety, and that balancing act sometimes means switching between agents or adjusting trough levels carefully.
Antiepileptic Drugs and Mood Stabilizers
Medications used to control seizures and stabilize mood are, paradoxically, among the drugs most commonly reported to cause cerebellar ataxia, a form of brain toxicity that produces unsteady gait, slurred speech, and poor coordination. A systematic review identified antiepileptic drugs, benzodiazepines, and cancer drugs as the most frequent causes, with some individual drugs having a “number needed to harm” below ten, meaning nerve damage was surprisingly common relative to the number of patients treated. Ataxia from most of these drugs is reversible once the medication is stopped or the dose is lowered, but lithium and certain cancer drugs are exceptions: persistent symptoms have been described even after discontinuation.10PubMed. Drug-induced cerebellar ataxia: a systematic review
Phenytoin, one of the oldest antiepileptic drugs still in use, has long been suspected of causing cerebellar atrophy with chronic use, particularly when blood levels run high. One MRI-based study of epilepsy patients on long-term phenytoin found that while group-level cerebellar volumes were not significantly different from controls, at least one individual on phenytoin showed markedly reduced cerebellar volume consistent with atrophy.11Journal of Radiology in Medicine. Magnetic resonance imaging (MRI) based cerebellum and brain volume measurement using Cavalier principle in epilepsy patients on long-term phenytoin and carbamazepine therapy The clinical takeaway is that most patients on phenytoin tolerate it without structural brain changes, but the drug has a narrow therapeutic window, and chronic toxicity in susceptible individuals is a real concern.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors are a newer class of cancer drugs that work by releasing the brakes on the immune system so it can attack tumors more aggressively. The tradeoff is that the unleashed immune system sometimes attacks the nervous system too. These drugs have been linked to a wide range of neurological side effects, including brain inflammation, a condition resembling myasthenia gravis (where muscles weaken because immune attacks disrupt the nerve-muscle junction), and various forms of peripheral neuropathy.12PubMed Central. Neurologic complications of immune checkpoint inhibitors
Some of these neurological reactions closely mimic paraneoplastic syndromes, rare conditions where the immune system, while fighting cancer, mistakenly generates antibodies against the brain or nerves. When immune checkpoint inhibitors trigger these syndromes, the damage tends to hit the central nervous system and is associated with the same types of neural antibodies seen in spontaneous paraneoplastic disease.13PubMed. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes A large pharmacovigilance analysis drawing on thousands of adverse-event reports confirmed that major checkpoint inhibitors including pembrolizumab, nivolumab, atezolizumab, ipilimumab, and durvalumab all produced strong safety signals for autoimmune encephalitis and other neurological events.14PubMed Central. Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
Anesthetics
General anesthetics raise a different kind of concern, one that has mainly played out in pediatric and neonatal research. In animal models, two groups of anesthetics have been shown to trigger cell death in developing neurons: drugs that block a type of excitatory brain receptor (such as ketamine and nitrous oxide) and drugs that boost an inhibitory brain receptor (such as propofol, midazolam, and volatile anesthetics like sevoflurane). Longer exposure times produced the most severe effects in young animals, including decreased synaptic density, mitochondrial damage, and impaired new neuron growth.15PubMed Central. Anesthesia-induced Developmental Neurotoxicity in Pediatric Population Whether these animal findings translate directly to human infants remains debated, but the concern has been significant enough to prompt regulatory attention and ongoing clinical studies.
Local anesthetics such as bupivacaine carry their own risks. When they accidentally enter the bloodstream in large amounts, they can cause seizures and cardiovascular collapse, a condition known as local anesthetic systemic toxicity (LAST). Treatment involves intravenous lipid emulsion, which works in part by pulling the fat-soluble anesthetic molecules out of affected tissues like the heart and brain.16PubMed Central. Lipid Emulsion for Treating Local Anesthetic Systemic Toxicity At the nerve itself, prolonged exposure of nerves to bupivacaine has been shown in animal studies to cause significant demyelination (stripping of the insulating sheath around nerve fibers) and inflammation.17PubMed Central. Local Anesthetic Schwann Cell Toxicity is Time and Concentration-Dependent Peripheral nerves are actually somewhat protected by their own barriers. Research suggests that less than 1% of a locally injected anesthetic actually penetrates through the nerve’s outer sheath to reach the nerve fibers inside; the rest is absorbed by surrounding fat and tissue or carried away by the bloodstream.18PubMed Central. Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers
Gadolinium Contrast Agents
Gadolinium-based contrast agents, used routinely to enhance MRI scans, have come under scrutiny after researchers discovered that gadolinium deposits accumulate in the brain even in patients with normal kidney function and an intact blood-brain barrier.19PubMed Central. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function The deposits concentrate in specific brain structures, particularly the dentate nuclei and globus pallidus, and accumulate with repeated doses.20The Lancet Neurology. Recommendations for the use of gadolinium-based contrast agents
Autopsy and imaging studies have confirmed that gadolinium ends up in endothelial walls and, to a lesser extent, in neural tissue itself, and that the concentration correlates strongly with cumulative dose.21PLOS ONE. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity – A systematic review Whether these deposits actually cause neurological symptoms in most patients remains an open question. Some patients who have received many contrast-enhanced MRIs report cognitive symptoms, headaches, and pain, but establishing a clear cause-and-effect link at the population level has been difficult. The discovery did prompt a shift toward using more chemically stable “macrocyclic” gadolinium agents, which appear to deposit less than the older “linear” formulations.
Recreational Drugs
MDMA (ecstasy) and amphetamines damage the brain’s chemical signaling systems in distinct ways. MDMA selectively and persistently damages the nerve terminals that release serotonin, while amphetamines harm both serotonin and dopamine systems.22PubMed Central. Neurotoxicity of drugs of abuse–the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines These are not the peripheral nerve injuries seen with chemotherapy drugs; instead, the damage occurs in the central nervous system and can show up as long-term changes in mood regulation, memory, and impulse control. The persistence of these changes after the drug is cleared from the body is what distinguishes true neurotoxicity from the temporary neurochemical disruption of a single dose.
Why Nerve Damage Sometimes Gets Worse After Stopping a Drug
One of the more unsettling aspects of drug-induced neuropathy is a phenomenon called coasting. With certain drugs, especially platinum compounds like cisplatin and oxaliplatin, nerve damage can continue to worsen for weeks or even months after the drug has been discontinued.23PubMed Central. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment Patients who felt relatively stable during treatment may find their numbness or pain intensifying well after their last infusion.
Coasting happens because the damage was set in motion before the drug was stopped. Platinum compounds that have already accumulated in nerve cell bodies continue to damage DNA and mitochondria, and the downstream effects of that injury take time to fully manifest. This is why oncologists are advised to consider dose modifications as soon as neuropathy symptoms begin to interfere with daily life, rather than waiting for severe impairment. Delaying that decision can mean the coasting effect pushes the patient into more severe, possibly irreversible territory.24PubMed. Chemotherapy-induced neuropathy
How Oxidative Stress Ties Many of These Drugs Together
A common thread runs through the mechanisms of many neurotoxic drugs: oxidative stress. When reactive oxygen species build up inside nerve cells, they do not just damage DNA and membranes. They also shut down axonal transport, the internal delivery system that moves essential cargo along the length of a nerve fiber. Laboratory research has shown that oxidative stress rapidly inhibits this transport, with mitochondrial cargo affected earlier and more severely than other types. This happens hours before any visible signs of nerve degeneration appear, suggesting that transport failure is an early event in the cascade leading to nerve damage, not a late consequence.25PubMed Central. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases
This matters for understanding why so many different drugs with different targets produce similar symptoms. Whether a drug directly attacks mitochondria (like cisplatin), disrupts the structural skeleton of nerve fibers (like paclitaxel), depletes a protective vitamin (like isoniazid), or triggers immune attack (like checkpoint inhibitors), the downstream path often converges on oxidative stress, energy failure, and transport breakdown inside the nerve. The shared endpoint helps explain why the symptoms feel so similar across drug classes: numbness, tingling, and burning pain in the longest nerves first, typically the feet and then the hands.
Emerging Blood Tests for Detecting Nerve Damage Early
Detecting drug-induced nerve damage before it becomes severe remains a major clinical challenge. Standard nerve conduction studies can identify damage to large nerve fibers but miss injury to small-diameter fibers. In one previous study, even though half of patients on oxaliplatin had moderate-to-severe neuropathy, only about 14% showed abnormalities on conventional nerve testing.26PubMed. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity That gap between what patients experience and what standard tests detect has pushed researchers toward blood-based biomarkers.
Neurofilament light chain (NfL), a structural protein released into the blood when nerve fibers break down, has shown promise. In animal models of chemotherapy-induced neuropathy, serum NfL levels tracked with the severity of axonal damage. Animals treated with paclitaxel, which causes more severe nerve injury than cisplatin, showed higher NfL levels, and the timing of the rise matched the progression of structural and functional nerve changes.26PubMed. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity In human patients, NfL levels have an advantage over nerve conduction studies: they reflect ongoing nerve damage in real time, whereas conduction studies mainly detect damage that has already been done. NfL levels also declined after chemotherapy ended, while nerve conduction abnormalities persisted for months, suggesting the blood test is more responsive to changes in either direction.27Scientific Reports. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy A simple blood draw during routine cancer-treatment labs could, in principle, flag nerve damage early enough to adjust treatment before the damage becomes irreversible. Clinical validation is still underway, but the trajectory is encouraging.